not used title
not used title
A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending – depending on whether they were administered at a hospital outpatient department or physician’s office. Not surprisingly, EBRI found employers and plans paid hospitals significantly more than physicians for the exact same treatment, suggesting employers and their workers could save money if these pricing differentials are addressed. This study comes on the tail of another EBRI study, which found hospital outpatient departments mark up the cost of oncology drugs by an average of 223%, which, in just one year of paying physician prices instead of hospital prices, could lead to employers saving an average of almost $10,000 per covered cancer patient.
Key findings from the report include:
1. Care is shifting from physician offices to more costly hospital outpatient departments. EBRI first determined where the 72 physician-administered outpatient medicines in their study are more likely to be administered and found similar results trending more broadly across the health care space.
- Nearly 60% of the physician-administered outpatient medicines studied were administered in a hospital outpatient department, while just one-third (34%) were administered in a lower cost doctor’s office.
- The shift to more costly sites of care is a growing trend. For example, in 2004, nearly all (94%) of chemotherapy infusions were administered in doctor’s offices. Just ten years later that percentage had dropped to 57% with a corresponding shift toward hospital outpatient departments administering that care. Increasing consolidation of providers is likely to exacerbate this trend.
This shift to more costly sites of care is significant because as hospitals continue to needlessly drive-up cost for treatments as compared to physician offices, the burden on the health care system – especially employers and workers – also grows.
2. Prices paid for drugs administered in a hospital-based outpatient setting are three times higher than prices paid in doctor offices. Hospitals’ rise in cost is meritless as EBRI examined the same 72 physician-administered treatments in each location.
- Unsurprisingly, average plan payments to hospital outpatient departments were triple what plan payments were to physician offices for the same unit of medication.
- EBRI found payments are higher to hospitals than in doctor offices for all but two of the 72 physician-administered outpatient drugs And prices for half of the drugs were marked up two-fold by hospitals relative to doctor offices.
- A previous analysis from the Moran Company found that nearly one in five hospitals charge 700% or more for medicines.
Not only are more treatments now being administered in hospital outpatient departments as compared to physician offices, but hospitals are also charging significantly more compared to physician offices for the exact same treatment.
3. Potential savings for employers, workers and the health care system are substantial if hospital outpatient departments did not overcharge for the same medicine administration as doctor offices. There is too much at stake for individuals, companies and the health care system as a whole to not hold hospitals accountable.
- In the aggregate, employers and workers could collectively save $10.3 billion annually if price differentials between hospital outpatient departments and doctor offices were eliminated for the 72 physician-administered outpatient medicines If we extended the savings to all physician administered medicines, aggregate savings would be $14.1 billion each year.
- On an individual basis, annual savings could be $80.21 for the 72 drugs examined in this paper and $110.03 for all physician-administered outpatient drugs if price differentials between the two locations were eliminated.
EBRI’s study underscores just how much hospitals are driving health care spending in the United States by unnecessarily marking up the cost of medicines. Yet, increasing provider consolidation is making it harder for employers to negotiate fair or competitive prices. Any conversation about ways to improve our health care system and lower costs for patients must include a discussion of these unfair hospital pricing practices that have implications for patients, employers and the entire health care system.
To learn more, read the study here and visit PhRMA.org/Cost.
Gabby Migliara
Gabby Migliara is a director of Public Affairs at PhRMA focusing on internal communications and PhRMA’s digital presence, including maintaining this website and executive social presence. She previously worked with the U.S. Census Bureau on marketing and communications for the 2020 Census campaign. Outside the office, Gabby enjoys trying new restaurants, hanging with her cat and exploring D.C. neighborhoods.
ICYMI: Hospital consolidation is driving up health care costs
August 27, 2026
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
June 25, 2026
A program off track: How 340B drives both hospital consolidation and system gaming
April 27, 2026
Washington Post Editorial Board says 340B has become “corporate welfare”
April 27, 2026
Hospitals drive nearly 80% of the U.S. health spending gap
March 25, 2026
Congress should look under the hood of 340B, hospitals don't want them to
March 19, 2026
Insurers routinely block seniors’ access to medicines in Medicare Part D
March 18, 2026
340B hospitals buy low and sell high, a new analysis shows
March 12, 2026
New report from Minnesota: 340B is generating billions for big hospitals
March 9, 2026
New study: PBMs and commercial insurers are quietly blocking prescription access
July 30, 2025
Latest analysis from Ohio exposes growing abuses of the 340B markup program
July 7, 2025
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
Guest Post: My health care vote
October 29, 2024
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
October 28, 2024
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
September 24, 2024
Key voter insights two months from Election Day
September 10, 2024
Patient priorities in the 2024 election
September 10, 2024
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
July 30, 2024
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
July 9, 2024
ICYMI: What patients care about this election year
June 24, 2024
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
June 5, 2024
Ongoing federal probes shed light on PBM and insurer practices
May 20, 2024
Critics repeat same, misleading narrative on potential “costs” of new medicines
May 7, 2024
WTAS: The consequences of consolidation and vertical integration
May 6, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
April 9, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
ICYMI: When middlemen get in the way, it’s the patients who lose
December 5, 2023
Increased use of prior authorization in Medicaid is blocking access for patients
November 28, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
One year to Election Day: Four voter priorities to watch
November 6, 2023
By the Numbers: 340B continues to climb in profits, dwindle with patient support
September 13, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
AARP’s latest misleading report
August 11, 2023
New report: Hospitals mark up medicine prices 500%
August 2, 2023
read more
August 2, 2023
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
July 26, 2023
Three things to know from the latest Patient Experience Survey
July 20, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
ICYMI: PBM exec admits choosing profits over patients
June 2, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
4 Things to know about PhRMA’s new 50-state poll
May 4, 2023
Three facts about health care spending
April 25, 2023
AHIP’s latest misinformation campaign & what it’s trying to hide
April 24, 2023
Nonprofit hospitals fall short on community benefit, studies show
April 24, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
March 29, 2023
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
March 2, 2023
Why Congress should prioritize fixing the 340B program
March 2, 2023
Holding pharmacy benefit managers accountable
February 23, 2023
Stopping pharmacy benefit managers from “gaming the system”
February 22, 2023
What they are saying: Nonprofit hospitals are gaming the system at the expense of patients
February 21, 2023
Senate hearing to examine bipartisan reforms to rein in middlemen
February 16, 2023
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
January 31, 2023
ICYMI: Cancer death rate continues to decline due to treatment advances
January 25, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
Study finds hepatitis C cure saved Medicaid $15 billion
January 5, 2023
340B program continues to drive shift in care to more expensive hospital settings
December 15, 2022
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
December 9, 2022
In their own words: Financial barriers exacerbate access challenges for insured Americans
December 8, 2022
Medicare Part D open enrollment and what recent changes mean for beneficiaries
November 17, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
In their own words: Insured Americans struggle to navigate complex coverage
October 26, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
October 7, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
Mental Illness Awareness Week – A time for reflection
October 3, 2022
Navigating the patient experience: Burdens and barriers standing between patients and their care
September 12, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
Insulin and reconciliation
August 15, 2022
Making coupons count for patients with HIV
August 8, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Patients win as West Virginia implements first-in-nation share the savings policy
July 8, 2022
3 things voters are concerned about when it comes to their health care coverage
July 7, 2022
Prescription drug prices are not fueling inflation
July 6, 2022
Copay assistance is a lifeline for patients. So why are insurers blocking it?
June 29, 2022
New poll shows voters sounding the alarm on health insurance companies and PBMs
June 6, 2022
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
May 31, 2022
Report finds PBMs are increasingly restricting patient access to medicines
May 25, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
Study finds insurance barriers disproportionately burden patients with chronic illness
May 4, 2022
What’s really happening when it comes to prescription drug costs
April 27, 2022
5 public opinion polling trends to watch
April 22, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
New analysis confirms hospitals markup prices for oncology therapies
April 21, 2022
How standardized plans can improve patients’ access to medicines
April 18, 2022
The patient experience: Uncovering the barriers to care for insured Americans
March 28, 2022
Correcting the record: Putting medicine costs and spending in context
March 24, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
March 14, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
March 8, 2022
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
February 28, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
February 8, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
New comments outline ways to counteract cost-shifting insurance trends
January 28, 2022
Patients need to pay less for their medicines. States can help.
January 26, 2022
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
January 25, 2022
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
January 21, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
New NHE data show the true picture of health care spending
December 22, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
The patient experience: Insurance design hurdles lead to access issues for too many Americans
October 28, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
What is Kaiser Family Foundation up to?
October 12, 2021
Recognizing Hepatitis R&D on World Hepatitis Day
July 28, 2021
340B hospitals among those that provide lowest levels of community benefit across the country
July 27, 2021
New reports shed light on key facts about medicines and affordability
June 8, 2021
How strengthening the biosimilar marketplace benefits patients
May 18, 2021
New report demonstrates development of new medicines relies on private sector expertise and investment
May 10, 2021
West Virginia becomes the first state to lower patient costs by sharing the savings
April 20, 2021
Getting the 340B program back on track in 2021
March 10, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
Insurers shift medicine costs to patients with severe chronic illnesses
February 1, 2021
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
December 17, 2020
Election insights: Voter priorities in the states
December 17, 2020
Fact Check: How hospitals continue to drive health care spending
December 3, 2020
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
November 19, 2020
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
October 23, 2020
Survey found insurance premiums grew faster than inflation in 2020
October 20, 2020
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
August 19, 2020
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
August 12, 2020
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
August 6, 2020
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
August 5, 2020
New data show commercially insured patients face increasingly high cost sharing for brand medicines
July 30, 2020
Payers subject 80% of new RA and MS patients to utilization management restrictions
July 22, 2020
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
June 1, 2020
New rule makes it harder for patients to lower their out-of-pocket costs
May 20, 2020
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
March 3, 2020
Fact Check: HCCI analysis overstates medicine spending and prices
February 19, 2020
Cancer medicines cost twice as much at hospitals, study finds
January 21, 2020
New GAO report: Some hospitals participating in 340B may not be eligible for the program
January 14, 2020
Nearly 50% of brand medicine spending goes to the supply chain and others
January 9, 2020
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
December 6, 2019
More evidence that medicine prices are growing at slowest rate in decades
October 4, 2019
Survey shows out-of-pocket costs top health care concern for voters
October 2, 2019
Four reasons why the radical Pelosi Plan is the wrong approach
September 24, 2019
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
September 10, 2019
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
August 20, 2019
Three things to know about the Part D GAO report
August 16, 2019
Setting the record straight on international reference pricing
July 16, 2019
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
July 9, 2019
Study finds hospitals continue to mark up medicines up to 500% of their cost
July 9, 2019
Three reasons why the latest Rx Savings Solutions analysis is misleading
July 2, 2019
"If Washington isn’t careful, we might leave innovation behind"
June 24, 2019
Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals
May 16, 2019
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
May 15, 2019
New study finds hospitals continue to push patients to costlier outpatient settings
May 13, 2019
4 Things to know about the IQVIA “Medicine Use and Spending” report
May 9, 2019
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
May 9, 2019
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
April 5, 2019
The PBM story you haven’t heard: Hidden fees quadrupled in two years
March 20, 2019
Health Affairs study misses the mark on medicine costs
January 28, 2019
New government data show medicine price growth continues to decline
January 18, 2019
New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program
December 18, 2018
Americans want to know more than just the list price of a medicine—and we’re answering their call
October 15, 2018
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
October 15, 2018
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
October 4, 2018
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
September 24, 2018
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
September 19, 2018
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
September 13, 2018
New study finds some hospitals mark up medicine prices at least 700 percent
September 5, 2018
69 percent of patients abandon medicines when cost sharing is more than $250
August 23, 2018
New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending
August 20, 2018
New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain
August 13, 2018
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
July 16, 2018
GAO again recommends improvements to 340B program
July 11, 2018
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
July 9, 2018
Medicare Part D cliff ahead
June 21, 2018
Part D cliff looms for seniors, as program stability could be in jeopardy
June 18, 2018
ICYMI: Analysis finds higher outpatient drug spending at 340B hospitals
June 18, 2018
Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually
May 17, 2018
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
May 15, 2018
New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D
May 9, 2018
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
May 4, 2018
Event tomorrow: Making the biopharmaceutical supply chain work for patients
May 2, 2018
Spending on medicines grew less than one percent in 2017
April 19, 2018
Patients pay the price when hospitals mark up cancer medicines
April 5, 2018
Advance price notification: A transparency measure that fails patients
March 29, 2018
340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?
March 28, 2018